Spinocerebellar Ataxia Type 3 Clinical Trial
Official title:
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3
Verified date | August 2023 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia type 3 (SCA3). The secondary objective of this study is to characterize the multiple-dose pharmacokinetics (PK) of BIIB132 administered via IT injection to participants with SCA3.
Status | Terminated |
Enrollment | 8 |
Est. completion date | July 25, 2023 |
Est. primary completion date | July 25, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Key Inclusion Criteria: - Diagnosis of SCA3 with CAG repeats =60 in ATXN3 gene. - Symptomatic ataxia with a screening Scale for Assessment and Rating of Ataxia (SARA) score 3 to 15 (still ambulatory) and a minimum SARA gait subscore of 1. - Able to ambulate 8 m independently without any assistive device. - Treatment naïve or on a stable dose of symptomatic therapy for a minimum of 4 weeks prior to screening. Key Exclusion Criteria: - Unstable psychiatric illness or untreated major depression within 90 days before screening. - History or screening magnetic resonance imaging (MRI) results show evidence of structural abnormalities that could contribute to the participant's clinical state other than findings typical of SCA3 or any finding that might pose a risk to the participant. - MRI brain findings of prior cerebellar stroke or clinical stroke within 12 months before screening. - History of brain surgery regardless of purpose. - Any contraindications to undergoing brain MRI. - History of, or ongoing, malignant disease, (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to screening). Participants with cancers in remission for longer than 5 years may be included. - History of epilepsy or the occurrence of seizures within 3 years prior to screening. - Evidence of untreated/unstable thyroid disease. - Poorly controlled diabetes mellitus. - History of alcohol or substance abuse within the past year prior to screening. - Use of off-label drugs for ataxia within 4 weeks prior to screening. - Prior enrollment in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 5 half-lives or 3 months, whichever is longer, prior to the screening visit. - Any antiplatelet [except for aspirin up to 100 milligrams per day (mg/day)] or anticoagulant medication that cannot be safely interrupted for an lumbar puncture (LP) procedure. - Any contraindications to LP procedures. - Participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study. - Prior enrollment in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months prior to screening visit. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Germany | Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE) | Bonn | Nordrhein Westfalen |
Germany | Universitaetsklinikum Essen Klinik für Neurologie | Essen | Nordrhein Westfalen |
Germany | UniversitaetsklinikumTübingen Neurologische Universitätsklinik | Tuebingen | Baden Wuerttemberg |
Israel | Tel Aviv Sourasky Medical Center | Tel Aviv | |
Netherlands | Universitair Medisch Centrum Groningen (UMCG) | Groningen | |
Netherlands | Radboudumc | Nijmegen | |
Portugal | Centro Hospitalar de Lisboa Norte | Lisboa | |
Portugal | Centro Hospitalar do Porto | Porto | |
United Kingdom | University College London Hospital (UCLH) | London | Greater London |
United Kingdom | Churchill Hospital | Oxford | Oxfordshire |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University of Florida, Center for Movement Disorders | Gainesville | Florida |
United States | Houston Methodist Research Institute | Houston | Texas |
United States | University of California - Los Angeles | Los Angeles | California |
United States | Columbia Univeristy Medical Center | New York | New York |
United States | Pennsylvania Neurological Institute | Philadelphia | Pennsylvania |
United States | Washington University | Saint Louis | Missouri |
United States | University of California San Francisco | San Francisco | California |
United States | University of Washington | Seattle | Washington |
United States | Movement Disorder Center Florida | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Biogen |
United States, Germany, Israel, Netherlands, Portugal, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events (AEs) | An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. | Day 1 to Day 267 | |
Primary | Number of Participants with Serious Adverse Events (SAEs) | A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a-life threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event. | Screening to Day 267 | |
Secondary | Area Under the Concentration-Time Curve (AUC) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 | ||
Secondary | Area Under the Concentration Versus Time Curve, from Time of Dosing (Time = 0) to Infinity (AUCinf) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 | ||
Secondary | Area Under the Concentration Versus Time Curve, from Time of Dosing (Time = 0) to Time of the Last Measurable Effect (AUClast) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 | ||
Secondary | Maximum Observed Concentration (Cmax) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 | ||
Secondary | Time to Reach Maximum Observed Concentration (Tmax) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 | ||
Secondary | Elimination Half-Life (t½) of BIIB132 | Pre-dose and at multiple timepoints post-dose on Day 1 up to Day 85 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00992771 -
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Completed |
NCT01096082 -
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Active, not recruiting |
NCT04229823 -
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
|
||
Active, not recruiting |
NCT04419974 -
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
|
||
Terminated |
NCT05490563 -
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Withdrawn |
NCT01096095 -
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Active, not recruiting |
NCT05826171 -
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
|
N/A | |
Recruiting |
NCT04399265 -
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
|
N/A | |
Completed |
NCT03885167 -
Identification of Biomarkers in Spinocerebellar Ataxia 3
|
||
Recruiting |
NCT05822908 -
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03378414 -
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
|
Phase 2 | |
Completed |
NCT05502432 -
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
|
N/A | |
Recruiting |
NCT04714307 -
Neuropsychiatry and Cognition in SCA3/MJD
|
||
Recruiting |
NCT05557786 -
Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
|
||
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|